Hormonal
Shorter leukocyte telomere length (LTL) is associated with a significantly higher risk of all-cause mortality and cardiovascular disease (CVD).
Your blood test's telomere length isn't a destiny, but a status report. Shorter telomeres correlate with higher heart disease and mortality risk. You can influence this trajectory by managing stress, exercising regularly, maintaining a healthy weight, and avoiding smoking, as these factors are linked to slower telomere shortening.
In epidemiologic studies, individuals with shorter telomeres are characterized by a higher mortality rate, which is nearly twice as high as in those with longer telomeres... The large scale prospective WOSCOPS study demonstrated a 44% increase in coronary artery events during 5.5 years of follow-up in individuals in the first quartile of LTL (shortest telomeres) compared to individuals in the fourth quartile (longest telomeres).
Why this rating
Supported by large-scale prospective studies (WOSCOPS, ESTHER) and meta-analyses, though observational nature limits causal inference.
Source
Telomere biology and age-related diseases
Markus Herrmann et al. · Clinical Chemistry and Laboratory Medicine (CCLM) · 2018
DOI 10.1515/cclm-2017-0870
More from this paper
- Lifestyle factors including regular physical activity, healthy diet (rich in vitamins/antioxidants), lower BMI, and no smoking are associated with longer telomeres and slower telomere shortening.Good
- Shorter telomeres in tumor tissue (breast, colon, prostate) are associated with advanced disease state, faster progression, and poorer survival, whereas leukocyte telomere length (LTL) shows inconsistent associations with cancer risk.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →